RECOMBINANT PRODUCTION AND THERMODYNAMICS OF INHIBITOR BINDING TO HUMAN HISTONE DEACETYLASES 6 AND 8

Goda Milinavičiūtė1, Justina Kazokaitė1, Daumantas Matulis1

1 Department of Biothermodynamics and Drug Design, Institute of Biotechnology, Vilnius University, Lithuania

The histone deacetylases (HDAC) are enzymes that deacetylate lysine residues in histones as well as in several other non-histone proteins. [1] The deacetylation of histones induces a condensed and transcriptionally inactive DNA. [2] There are 18 HDAC family members in human genome. They are divided into 4 different groups according to their catalytic pockets and mechanisms of action. [3] Several HDAC isoforms, such as HDAC6, potentially play a role in schizophrenia, cancer and Alzheimer's disease. Furthermore, alterations in acetylation have been implicated in neurodegenerative disorders, including Huntington's and Parkinson's diseases. [2]

HDAC6 deacetylates histones and many other substrates. For example, HDAC6 was shown to take part in the microtubule network by acting as a specific α-tubulin deacetylase. [1] HDAC8 is mostly expressed in smooth muscle and the function is related with muscle contractility. In addition, HDAC8 has been shown to be important for the growth of human tumor cell lines. [4] Therefore, both HDAC6 and HDAC8 are potential drug targets. Thus, the production of the recombinant HDAC6 and HDAC8 and the investigation of inhibitor binding affinity to them are important for the design of new compounds with desired affinity properties.

The gene of human recombinant HDAC6 was cloned into four different plasmids containing N-terminal His-tag, C-terminal His-tag and N-terminal GST-tag. All of the constructs were expressed in various E. coli strains. Unfortunately, efforts to purify the recombinant HDAC6 by affinity and ion exchange chromatographies have not yet succeeded. However, human recombinant HDAC8 with a C-terminal His-tag was expressed in E. coli strain and successfully purified by affinity chromatography. The thermodynamics of interaction between HDAC8 and inhibitors such as Tubastatin A and Belinostat, which is clinically used for the treatment of cancer, were determined by the fluorescent thermal shift assay (FTSA) and isothermal titration calorimetry (ITC). Tubastatin A exhibited a dissociation constant of 14.29 μM for HDAC8. Belinostat bound HDAC8 with 7.69 μM affinity. Furthermore, the thermal stability of HDAC8 was determined at various pH and in the presence of buffers and salts by FTSA. HDAC8 was the most stable in sodium phosphate buffer at pH 6.0-7.0. The recombinant human HDAC8 was successfully produced and characterized and the search for novel inhibitors is in progress.


[1] Claudia Simoes-Pires et al. HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs? Molecular Neurodegeneration, 8:7 (2013)

[2] Florence F. Wagner et al. Small molecule inhibitors of Zinc-dependent Histone deacetylases. Neurotherapeutics, 10:589-60 (2013)

[3] Olaf Witt et al. HDAC family: What are the cancer relevant targets? Cancer Letters, 277: 8-21 (2009)

[4] Jinhong Feng et al. Expression, purification, and S-nitrosylation of recombinant histone deacetylase 8 in Echerichia coli. BioScience Trends, 5(1):17-22 (2011)